Positive topline results from the TROPION-Breast01 phase 3 trial showed datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival compared to investigator’s choice of chemotherapy in patients with inoperable or metastatic hormone receptor positive, HER2 low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy.
